BAM
SNDX icon

Bellevue Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Bellevue Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-79
Closed -$1.66K – 481
2025
Q4 		$1.66K Hold
79
– – ﹤0.01% 458
2025
Q3 		$1.22K Buy
+79
New +$1.03K ﹤0.01% 479

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Bellevue Asset Management's SNDX Position: Q1 2026 in Review

Bellevue Asset Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2026, closing a stake of 79 shares — an estimated $1.66K sold.

Bellevue Asset Management first reported a position in SNDX in Q3 2025 and held it in 2 quarters. The position peaked at $1.66K in Q4 2025. 247 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Bellevue Asset Management reported no remaining Syndax Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bellevue Asset Management sold 79 Syndax Pharmaceuticals shares in Q1 2026, an estimated $1.66K.
  • Bellevue Asset Management first reported a position in Syndax Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Bellevue Asset Management's Syndax Pharmaceuticals position peaked at $1.66K in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Bellevue Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.